• News
PEGS Boston – Advancing Bispecific Antibodies and Combination Therapy to the Clinic

PEGS Boston – Advancing Bispecific Antibodies and Combination Therapy to the Clinic

19th annual PEGS Boston - Nicolas Fischer -


Light Chain Bioscience is very pleased to have Nicolas Fischer, CEO, speaking at the Protein Engineering Summit in Boston on CD28 co-stimulatory bispecific antibody programs in the session entitled “Advancing Bispecific Antibodies and Combination Therapy to the Clinic


May 15-19, 2023

Boston MA, Hynes convention center & virtual

Back to News

First patient dosed with NILK-2301 in Phase I clinical trial

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer


Read more

LinkedIn